Clinical Trial Update: Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial exploring DPX-Survivac with low-dose cyclophosphamide and pembrolizumab in selected advanced solid tumors; currently active/not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Hepatocellular Carcinoma
• Microsatellite Instability-high
• Non-small Cell Lung Cancer
• Ovarian Cancer

Drugs mentioned

• DPX-Survivac
• Pembrolizumab (pembrolizumab)
• cyclophosphamide (low-dose) (cyclophosphamide)

Snippet

Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.) | Conditions: Ovarian Cancer, Hepatocellular Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING